Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer

• Published in: Breast cancer research : BCR 2017-08, Vol.19 (1), p.101-101, Article 101
• Main Authors: Yuan, Yuan, Vora, Nilesh, Sun, Can-Lan, Li, Daneng, Soto-Perez-de-Celis, Enrique, Mortimer, Joanne, Luu, The-Hang, Somlo, George, Waisman, James, Smith, David, Chao, Joseph, Katheria, Vani, Synold, Timothy, Tran, Vivi, Mi, Shu, Levi, Abrahm, Arsenyan, Anait, Choi, Jennifer, Zavala, Laura, Yost, Susan, Hurria, Arti
• Format: Article
• Language: English
• Subjects: Activities of Daily Living; Adult; Age; Aged; Aged, 80 and over; Aging; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological markers; Biomarkers; Blood coagulation; Blood Coagulation Factors; Breast Cancer; Breast Neoplasms - blood; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; C-Reactive Protein; Chemotherapy; Coagulation; Coagulation factors; Comorbidity; Cytokines; Drug dosages; Female; Fibrin Fibrinogen Degradation Products; Frailty; Humans; Inflammation; Inflammation Mediators - blood; Interleukin 6; Interleukin-6 - blood; Medical prognosis; Middle Aged; Neoplasm Staging; Older adults; Older people; Patients; Peripheral blood; Quality of Life; Toxicity; Treatment Outcome; Womens health
• ISSN: 1465-542X; 1465-5411; 1465-542X
• DOI: 10.1186/s13058-017-0895-5

Chemotherapy decreases the risk of relapse and mortality in early-stage breast cancer (BC), but it comes with the risk of toxicity. Chemotherapy efficacy depends on relative dose intensity (RDI), and an RDI